Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Squamous NSCLC, Immunotherapy

Naiyer Rizvi

MD

🏢Columbia University Irving Medical Center🌐USA

Price Family Professor of Medicine and Director of Thoracic Oncology

79
h-index
0
Key Papers
0
Key Contributions

👥Biography 个人简介

Dr. Naiyer Rizvi is a pioneer in cancer immunotherapy who established the connection between mutational burden and immunotherapy response in lung cancer. His work has particular relevance to squamous NSCLC, which arises predominantly in smokers and carries high mutational burden. He has been a principal investigator in landmark immunotherapy trials for squamous NSCLC and has contributed foundational biomarker research.

Share:

🧪Research Fields 研究领域

squamous NSCLC immunotherapy
TMB biomarker squamous
pembrolizumab KEYNOTE-158
tobacco-associated tumors immunotherapy
checkpoint inhibitor biomarkers

🎓Key Contributions 主要贡献

Representative Works 代表性著作

📄Data Sources 数据来源

Last updated: 2026-04-01 | All information from publicly available academic sources

关注 Naiyer Rizvi 的研究动态

Follow Naiyer Rizvi's research updates

留下邮箱,当我们发布与 Naiyer Rizvi(Columbia University Irving Medical Center)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment